- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Gilead to Acquire Tubulis, Expanding Antibody-Drug Conjugate Portfolio
The deal adds a potentially best-in-class ADC and next-generation platform to Gilead's pipeline.
Apr. 7, 2026 at 5:55pm
Got story updates? Submit your updates here. ›
Gilead's strategic acquisition of Tubulis and its antibody-drug conjugate platform aims to strengthen the company's oncology pipeline and capabilities.Foster City TodayGilead Sciences, Inc. has announced a definitive agreement to acquire Tubulis GmbH, a biopharmaceutical company focused on developing antibody-drug conjugates (ADCs). The acquisition will add Tubulis' potentially best-in-class ADC candidate and next-generation platform to Gilead's pipeline, strengthening the company's capabilities in this growing oncology modality.
Why it matters
The acquisition of Tubulis aligns with Gilead's strategy to expand its oncology portfolio and capabilities through targeted, strategic deals. ADCs are a rapidly evolving class of cancer therapeutics that combine the targeting ability of monoclonal antibodies with the cancer-killing power of cytotoxic payloads, potentially offering improved efficacy and tolerability compared to traditional chemotherapies.
The details
Under the terms of the agreement, Gilead will acquire Tubulis for an upfront payment of $1.9 billion, with additional potential milestone payments. Tubulis' lead ADC candidate and its next-generation ADC platform will complement Gilead's existing oncology pipeline and R&D expertise.
- Gilead announced the acquisition on April 7, 2026.
- The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions.
The players
Gilead Sciences, Inc.
A leading biopharmaceutical company focused on developing innovative medicines for life-threatening diseases, including cancer and viral infections.
Tubulis GmbH
A biopharmaceutical company focused on developing antibody-drug conjugates (ADCs), a rapidly evolving class of cancer therapeutics.
What they’re saying
“The acquisition of Tubulis represents an important strategic step in strengthening our oncology pipeline and capabilities. Tubulis' potentially best-in-class ADC candidate and next-generation platform complement our existing expertise and will help accelerate our efforts to bring innovative cancer therapies to patients.”
— Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences
What’s next
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions.
The takeaway
This acquisition demonstrates Gilead's commitment to expanding its oncology portfolio through strategic deals that bolster its capabilities in emerging and promising therapeutic modalities like antibody-drug conjugates. The addition of Tubulis' assets and expertise will strengthen Gilead's position in the rapidly evolving ADC space.
